AstraZeneca Pharmaceuticals LP
NEWS
Many companies appear to be getting their clinical trial news updated ahead of the holidays. Here’s a look.
Vir Biotechnology and GlaxoSmithKline dosed the first patient in a new sub-trial of a Phase III study assessing the monoclonal antibody VIR-7831 as a potential treatment of hospitalized adults diagnosed with COVID-19.
Despite some setbacks, the company anticipates its vaccine could be available for use in the United Kingdom within the next several weeks.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 15, 2020.
The deal has been approved by both companies’ boards and is expected to close in the third quarter of 2021.
AstraZeneca, which is jointly developing a COVID-19 vaccine with the University of Oxford, plans to begin clinical trials testing its vaccine in combination with Russia’s Sputnik V vaccine by the end of the year.
A COVID-19 vaccine being developed by CSL Ltd., and the University of Queensland was scrapped this week after numerous vaccine recipients reported receiving false positives on certain HIV tests.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
AstraZeneca and the University of Oxford published an interim analysis of their four Phase III clinical trials of AZD1222, their COVID-19 vaccine.
JOBS
IN THE PRESS